Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples